Carboplatin-Etoposide Versus Topotecan as Second-Line Treatment for Sensitive Relapsed Small-Cell Lung Cancer: Phase 3 Trial

被引：6
|
作者：
Baize, N. [1 ]
Monnet, I. [2 ]
Greillier, L. [3 ]
Geier, M. [4 ]
Lena, H. [5 ]
Janicot, H. [6 ]
Vergnenegre, A. [7 ]
Crequit, J. [8 ]
Lamy, R. [9 ]
Auliac, J. B. [10 ]
Le Treut, J. [11 ]
Le Caer, H. [12 ]
Gervais, R. [13 ]
Dansin, E. [14 ]
Madroszyk, A. [15 ]
Renault, P. [16 ]
Legarff, G. [17 ]
Schott, R. [18 ]
Saulnier, P. [1 ]
Chouaid, C. [2 ]
机构：
[1] CHU Angers, Angers, France
[2] Chi Creteil, Pneumol, Creteil, France
[3] Ap Marseille, Serv Oncol Multidisciplinaire & Innovat Therapeut, Marseille, France
[4] CHU Brest, Inst Cancerol & Hematol, Brest, France
[5] CHU Rennes, Serv Pneumol, Rennes, France
[6] Hop Montpied, CHU, Clermont Ferrand, France
[7] CHU Limoges, Limoges, France
[8] Ch Beauvais, Beauvais, France
[9] Ch Bretagen Sud, Lorient, France
[10] Ctr Hosp F Quesnay, Mantes La Jolie, France
[11] Ctr Hosp Pays Aix, Aix En Provence, France
[12] Ctr Hosp St Brieuc, St Brieuc, France
[13] Ctr Francois Baclesse, Caen, France
[14] Ctr Oscar Lambret, Lille, France
[15] Inst Paoli Calmette, Marseille, France
[16] Ch Pau, Pau, France
[17] Ctr Hosp St Brieux, St Brieux, France
[18] Clcc Paul Strauss, Strasbourg, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Small Cell Lun Cancer; second line; phase; 3; trial;
D O I：
10.1016/j.jtho.2019.08.490
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA15.02
引用
收藏
页码：S246 / S246
页数：1
相关论文
共 50 条
  • [1] Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial
    Baize, Nathalie
    Monnet, Isabelle
    Greillier, Laurent
    Geier, Margaux
    Lena, Herve
    Janicot, Henri
    Vergnenegre, Alain
    Crequit, Jacky
    Lamy, Regine
    Auliac, Jean-Bernard
    Letreut, Jacques
    Le Caer, Herve
    Gervais, Radj
    Dansin, Eric
    Madroszyk, Anne
    Renault, Patrick-Aldo
    Le Garff, Gwenaelle
    Falchero, Lionel
    Berard, Henri
    Schott, Roland
    Saulnier, Patrick
    Chouaid, Christos
    LANCET ONCOLOGY, 2020, 21 (09): : 1224 - 1233
  • [2] Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
    von Pawel, Joachim
    Jotte, Robert
    Spigel, David R.
    O'Brien, Mary E. R.
    Socinski, Mark A.
    Mezger, Joerg
    Steins, Martin
    Bosquee, Leon
    Bubis, Jeffrey
    Nackaerts, Kristiaan
    Trigo, Jose M.
    Clingan, Philip
    Schuette, Wolfgang
    Lorigan, Paul
    Reck, Martin
    Domine, Manuel
    Shepherd, Frances A.
    Li, Shaoyi
    Renschler, Markus F.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (35) : 4012 - U160
  • [3] Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer
    Chouaid, Christos
    Monnet, Isabelle
    Baize, Nathalie
    LANCET ONCOLOGY, 2020, 21 (12): : E546 - E546
  • [4] Randomized phase 3 trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer (SCLC)
    von Pawel, J.
    Jotte, R.
    Spigel, D. R.
    Socinski, M. A.
    O'brien, M. E. R.
    Pashold, E. H.
    Mezger, J.
    Steins, M.
    Bosquee, L.
    Bubis, J.
    Nackaerts, K.
    Trigo, J. M.
    Clingan, P.
    Schuette, W.
    Lorigan, P. C.
    Reck, M.
    Domine, M.
    Shepard, F. A.
    Mcnally, R.
    Renschler, M. F.
    ONKOLOGIE, 2011, 34 : 122 - 124
  • [5] Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial
    Goto, Koichi
    Ohe, Yuichiro
    Shibata, Taro
    Seto, Takashi
    Takahashi, Toshiaki
    Nakagawa, Kazuhiko
    Tanaka, Hiroshi
    Takeda, Koji
    Nishio, Makoto
    Mori, Kiyoshi
    Satouchi, Miyako
    Hida, Toyoaki
    Yoshimura, Naruo
    Kozuki, Toshiyuki
    Imamura, Fumio
    Kiura, Katsuyuki
    Okamoto, Hiroaki
    Sawa, Toshiyuki
    Tamura, Tomohide
    LANCET ONCOLOGY, 2016, 17 (08): : 1147 - 1157
  • [6] Carboplatin plus etoposide or topotecan for small-cell lung cancer
    Arrieta, Oscar
    Lara-Mejia, Luis
    Zatarain-Barron, Zyanya Lucia
    LANCET ONCOLOGY, 2020, 21 (09): : 1132 - 1134
  • [7] Efficacy of Second-line Chemotherapy in Patients With Sensitive Relapsed Small-cell Lung Cancer
    Wakuda, Kazushige
    Miyawaki, Taichi
    Miyawaki, Eriko
    Mamesaya, Nobuaki
    Kawamura, Takahisa
    Kobayashi, Haruki
    Omori, Shota
    Nakashima, Kazuhisa
    Ono, Akira
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Murakami, Haruyasu
    Mori, Keita
    Endo, Masahiro
    Takahashi, Toshiaki
    IN VIVO, 2019, 33 (06): : 2229 - 2234
  • [8] OUR EXPERIENCE WITH TOPOTECAN AS SECOND-LINE TREATMENT OF PATIENTS WITH RELAPSED SMALL CELL LUNG CANCER
    Davidov, Deyan
    JOURNAL OF IMAB, 2010, 16 (03): : 70 - 73
  • [9] Second-line treatment of small-cell lung cancer
    MacCallum C.
    Gillenwater H.H.
    Current Oncology Reports, 2006, 8 (4) : 258 - 264
  • [10] Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).
    Jotte, R.
    Von Pawel, J.
    Spigel, D. R.
    Socinski, M. A.
    O'Brien, M.
    Paschold, E. H.
    Mezger, J.
    Steins, M.
    Bosquee, L.
    Bubis, J. A.
    Nackaerts, K.
    Perez, J. M. Trigo
    Clingan, P. R.
    Schuette, W.
    Lorigan, P.
    Reck, M.
    Domine, M.
    Shepherd, F. A.
    McNally, R.
    Renschler, M. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345